|
|
Avicenna Journal of Clinical Microbiology and Infection، جلد ۳، شماره ۴، صفحات ۰-۰
|
|
|
| عنوان فارسی |
Assessment of the Response to Treatment in Patients with the Hepatitis C Virus Infection: A Quantitative Study by Focusing on Virologic and Biochemical Responses |
|
| چکیده فارسی مقاله |
Objectives The main goal of the treatment of the hepatitis C virus (HCV) infection is reduction and elimination of viruses as well as achieving high sustained viral response (SVR). The present study aimed to assess response to treatment of HCV infection by focusing on virological and biochemical aspects. Methods This study was performed in Hamadan, Iran on HCV infected patients who were referred between 2009 and 2013. All participants were under the treatment with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). The duration of treatment varied based on the HCV genotype as 24 weeks for genotypes 2 and 3, and 48 weeks for other genotypes. Conclusions Even with the introduction of new drugs and interferon free protocols in treatment of hepatitis C infection it seems that the IFN-based treatment is still used in low/middle income countries for treatment-naive patients with HCV genotype 3. Results Of the 186 patients with HCV infection, 52.8% had a genotype of 3a and 35.6% had a genotype of 1a/b. Three months after treatment, 75 patients were willing to do quantitative PCR and early virologic response was observed in 58 cases (78.4%). Also, 112 patients were assessed after completing the treatment (75 patients in 24 weeks and 37 patients in 48 weeks treatment protocol) and the end-of-treatment response (ETR) was 94.7% and 86.5% respectively. Amongst the 103 patients with ETR, 76 were followed up six months after treatment and the PCR was negative in 71 cases (SVR = 93.4). With the progress and completion of the treatment, improvement is observed in liver function tests. |
|
| کلیدواژه‌های فارسی مقاله |
Hepatitis C،Treatment Outcome،PEG- IFN،Ribavirin |
|
| عنوان انگلیسی |
Assessment of the Response to Treatment in Patients with the Hepatitis C Virus Infection: A Quantitative Study by Focusing on Virologic and Biochemical Responses |
|
| چکیده انگلیسی مقاله |
Objectives The main goal of the treatment of the hepatitis C virus (HCV) infection is reduction and elimination of viruses as well as achieving high sustained viral response (SVR). The present study aimed to assess response to treatment of HCV infection by focusing on virological and biochemical aspects. Methods This study was performed in Hamadan, Iran on HCV infected patients who were referred between 2009 and 2013. All participants were under the treatment with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). The duration of treatment varied based on the HCV genotype as 24 weeks for genotypes 2 and 3, and 48 weeks for other genotypes. Conclusions Even with the introduction of new drugs and interferon free protocols in treatment of hepatitis C infection it seems that the IFN-based treatment is still used in low/middle income countries for treatment-naive patients with HCV genotype 3. Results Of the 186 patients with HCV infection, 52.8% had a genotype of 3a and 35.6% had a genotype of 1a/b. Three months after treatment, 75 patients were willing to do quantitative PCR and early virologic response was observed in 58 cases (78.4%). Also, 112 patients were assessed after completing the treatment (75 patients in 24 weeks and 37 patients in 48 weeks treatment protocol) and the end-of-treatment response (ETR) was 94.7% and 86.5% respectively. Amongst the 103 patients with ETR, 76 were followed up six months after treatment and the PCR was negative in 71 cases (SVR = 93.4). With the progress and completion of the treatment, improvement is observed in liver function tests. |
|
| کلیدواژه‌های انگلیسی مقاله |
Hepatitis C,Treatment Outcome,PEG- IFN,Ribavirin |
|
| نویسندگان مقاله |
پیمان عینی | peyman eini
brucellosis research centre, department of infectious diseases, hamadan university of medical sciences, hamadan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی همدان (Hamadan university of medical sciences)
مژگان ممانی | mojgan mamani
department of infectious diseases, hamadan university of medical sciences, hamadan, iran; brucellosis research centre, sina hospital, mirzadeh-eshghi street, hamadan 65168, iran. tel 98-8138274192, fax 98-8138276010
سازمان اصلی تایید شده: دانشگاه علوم پزشکی همدان (Hamadan university of medical sciences)
فاطمه کشاورز | fatemeh keshavarz
general practitioner, hamadan university of medical sciences, hamadan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی همدان (Hamadan university of medical sciences)
عباس مرادی | abbas moradi
department of community medicine, hamadan university of medical sciences, hamadan, iran
سازمان اصلی تایید شده: دانشگاه علوم پزشکی همدان (Hamadan university of medical sciences)
|
|
| نشانی اینترنتی |
http://www.ajcmicrob.com/index.php?page=article&article_id=41142 |
| فایل مقاله |
اشکال در دسترسی به فایل - ./files/site1/rds_journals/1795/article-1795-276871.pdf |
| کد مقاله (doi) |
10.17795/ajcmi-41142 |
| زبان مقاله منتشر شده |
fa |
| موضوعات مقاله منتشر شده |
|
| نوع مقاله منتشر شده |
research-article |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|